High IL-8 at baseline (> 23 pg/ml) was associated with shorter OS in squamous NSCLC patients treated with nivolumab (Fig. 3A, CheckMate 017, p = 0.0051) and non-squamous NSCLC patients treated with nivolumab (Fig. 3B, CheckMate 057, p < 0.0001). This evidence concerns the gene CXCL8 and non-small cell lung carcinoma.